Given the predominance of single‐arm studies in this field, our study aimed to systematically review and meta‐analyze the existing evidence on the efficacy and safety of FRα‐targeting ADCs, providing a comprehensive and evidence‐based reference for clinicians treating recurrent ovarian cancer. Here, FOLR1 is linked to ovarian cancer.